Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a, Sequential Cohort, Single Ascending Dose Study of the Safety, Tolerability, Biodistribution, and Pharmacodynamics of EBT 101 in Aviremic HIV-1 Infected Adults on Stable Antiretroviral Therapy

X
Trial Profile

A Phase 1/2a, Sequential Cohort, Single Ascending Dose Study of the Safety, Tolerability, Biodistribution, and Pharmacodynamics of EBT 101 in Aviremic HIV-1 Infected Adults on Stable Antiretroviral Therapy

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs EBT 101 (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; First in man
  • Sponsors Excision BioTherapeutics
  • Most Recent Events

    • 13 May 2024 Results published in an Excision BioTherapeutics Media Release.
    • 10 Apr 2024 According to an Excision BioTherapeutics Media Release, the trial will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting.
    • 25 Oct 2023 According to an Excision BioTherapeutics Media Release, company plans to dose escalate to its next dose level (3.0x1012 vg/kg) in Q4 2023 and present additional data in 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top